Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?
Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory properties. The breadth of their usage is due in no sma...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01626/full |
| _version_ | 1819159021277413376 |
|---|---|
| author | Paul Lohan Oliver Treacy Oliver Treacy Matthew D. Griffin Matthew D. Griffin Thomas Ritter Thomas Ritter Aideen E. Ryan Aideen E. Ryan |
| author_facet | Paul Lohan Oliver Treacy Oliver Treacy Matthew D. Griffin Matthew D. Griffin Thomas Ritter Thomas Ritter Aideen E. Ryan Aideen E. Ryan |
| author_sort | Paul Lohan |
| collection | DOAJ |
| description | Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory properties. The breadth of their usage is due in no small part to the vast quantity of published studies showing their ability to modulate multiple immune cell types of both the innate and adaptive immune response. While patient-derived (autologous) MSC may be the safer choice in terms of avoiding unwanted immune responses, factors including donor comorbidities may preclude these cells from use. In these situations, allogeneic MSC derived from genetically unrelated individuals must be used. While allogeneic MSC were initially believed to be immune-privileged, substantial evidence now exists to prove otherwise with multiple studies documenting specific cellular and humoral immune responses against donor antigens following administration of these cells. In this article, we will review recent published studies using non-manipulated, inflammatory molecule-activated (licensed) and differentiated allogeneic MSC, as well as MSC extracellular vesicles focusing on the immune responses to these cells and whether or not such responses have an impact on allogeneic MSC-mediated safety and efficacy. |
| first_indexed | 2024-12-22T16:33:56Z |
| format | Article |
| id | doaj.art-049c409f88fa4cd8b33bc753825f22e0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T16:33:56Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-049c409f88fa4cd8b33bc753825f22e02022-12-21T18:20:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-11-01810.3389/fimmu.2017.01626313870Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?Paul Lohan0Oliver Treacy1Oliver Treacy2Matthew D. Griffin3Matthew D. Griffin4Thomas Ritter5Thomas Ritter6Aideen E. Ryan7Aideen E. Ryan8Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandRegenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandDiscipline of Pharmacology and Therapeutics, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandRegenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandCURAM Centre for Research in Medical Devices, National University of Ireland, Galway, IrelandRegenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandCURAM Centre for Research in Medical Devices, National University of Ireland, Galway, IrelandRegenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandDiscipline of Pharmacology and Therapeutics, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, IrelandMesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory properties. The breadth of their usage is due in no small part to the vast quantity of published studies showing their ability to modulate multiple immune cell types of both the innate and adaptive immune response. While patient-derived (autologous) MSC may be the safer choice in terms of avoiding unwanted immune responses, factors including donor comorbidities may preclude these cells from use. In these situations, allogeneic MSC derived from genetically unrelated individuals must be used. While allogeneic MSC were initially believed to be immune-privileged, substantial evidence now exists to prove otherwise with multiple studies documenting specific cellular and humoral immune responses against donor antigens following administration of these cells. In this article, we will review recent published studies using non-manipulated, inflammatory molecule-activated (licensed) and differentiated allogeneic MSC, as well as MSC extracellular vesicles focusing on the immune responses to these cells and whether or not such responses have an impact on allogeneic MSC-mediated safety and efficacy.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01626/fullallogeneicallo-mesenchymal stromal cellanti-donor immune responseimmunogeniciyinflammationimmunomodulation |
| spellingShingle | Paul Lohan Oliver Treacy Oliver Treacy Matthew D. Griffin Matthew D. Griffin Thomas Ritter Thomas Ritter Aideen E. Ryan Aideen E. Ryan Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? Frontiers in Immunology allogeneic allo-mesenchymal stromal cell anti-donor immune response immunogeniciy inflammation immunomodulation |
| title | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? |
| title_full | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? |
| title_fullStr | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? |
| title_full_unstemmed | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? |
| title_short | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? |
| title_sort | anti donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles are we still learning |
| topic | allogeneic allo-mesenchymal stromal cell anti-donor immune response immunogeniciy inflammation immunomodulation |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01626/full |
| work_keys_str_mv | AT paullohan antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT olivertreacy antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT olivertreacy antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT matthewdgriffin antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT matthewdgriffin antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT thomasritter antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT thomasritter antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT aideeneryan antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning AT aideeneryan antidonorimmuneresponseselicitedbyallogeneicmesenchymalstemcellsandtheirextracellularvesiclesarewestilllearning |